Welcome to our dedicated page for REDWOOD SCIENTIFIC TECH news (Ticker: $RSCI), a resource for investors and traders seeking the latest updates and insights on REDWOOD SCIENTIFIC TECH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect REDWOOD SCIENTIFIC TECH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of REDWOOD SCIENTIFIC TECH's position in the market.
Rhea-AI Summary
Redwood Scientific Technologies Inc. (OTC: RSCI) announced a strategic shift in product development to focus on enhancing nicotine replacement therapy products TBX-FREE™ and TBX VAPE-FREE™. This decision follows research linking e-cigarette use to heart failure risks, emphasizing the need for safer alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.36%
Tags
-
Rhea-AI Summary
Redwood Scientific Technologies Inc. (RSCI) achieved significant milestones in 2023, focusing on innovative pharmaceutical products. CEO Jason Cardiff is leading the company's initiative to establish an oral thin film manufacturing hub in the US, aiming for self-reliance. Redwood plans to transition to the OTCQB platform in April 2024, after submitting an application for NASDAQ listing. Key highlights include financial audit completion, patent approvals, product launch readiness, and partnerships for clinical testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
-
Rhea-AI Summary
Redwood Scientific Technologies Inc. has engaged George Mason University to conduct a clinical effectiveness study of its TBX-Free oral strips for smoking and e-cigarette cessation. The company aims to bring a nicotine-free product to market to help millions of adults and youths overcome nicotine addiction. The TBX-Free oral strips rely on the power of cytisine, a more effective active ingredient than nicotine, found in golden rain trees. The company is committed to developing safe and effective products to address the crisis of nicotine addiction, especially among youth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.19%
Tags
Rhea-AI Summary
Redwood Scientific Technologies (RSCI OTC PINK) has secured conditional approval from the Institutional Review Board (IRB)/Central Institutional Review Board (CIRB) for groundbreaking clinical studies on a new Oral Thin Film Strip to address nicotine addiction in vape devices and TBX FREE for traditional cigarettes. This milestone signifies a significant advancement in Redwood's efforts to combat nicotine addiction and marks a crucial step forward in bringing nicotine-free solutions to the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.98%
Tags
-
Rhea-AI Summary
Redwood Scientific Technologies successfully files S1 registration statement with the SEC and provides updates on clinical trial progress for TBX FREE and TBX VAPE FREE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Redwood Scientific Technologies Inc. corrects a previous press release, clarifying that the arrangement with Silk Road Ent., Inc. was a 'Marketing Consulting Agreement' and not a partnership. Redwood has canceled the agreement and prohibited Silk Road from marketing or selling its premarket development products. CEO Jason Cardiff expresses confidence in regulatory compliance and establishing beneficial partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Redwood Scientific Technologies Inc. files a new patent for its Oral Thin Film (OTF) manufacturing system, aiming to revolutionize the pharmaceutical industry. The system offers precise administration of nano dosages of active ingredients, enhancing bioavailability and patient outcomes. Redwood is also working on an effectiveness study for its flagship product, TBX-FREE, with promising feedback from customers. The study results are expected to be published in the fourth quarter of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
REDWOOD SCIENTIFIC TECH
OTC:RSCI
RSCI Rankings
RSCI Stock Data
148.68M
All Other Miscellaneous Chemical Product and Preparation Manufacturing
Manufacturing
United States of America
Claremont
About RSCI
redwood scientific technologies (rsci) is a pharmaceutical delivery company located in upland. ca. rsci develops, operates, and markets sublingual delivery products. we are the global leader in thin film oral delivery strips for lifestyle issues. our leading product tbx-free, is an aid to help with the addiction to nicotine. all rsci products are registered with the fda as over the counter and are listed in the national drug directory. rsci has a robust product pipeline that will be released over the next four years. our current products that are available range from a sleep aid to men’s sexual dysfunction aids. rsci's market strategy focuses on direct to consumers with a secondary emphasis on large wholesale distributors. in addition, rsci is in the developing stages of a complete product line for children. the first product to be released within that line will the version of children's ibuprofen in an easy to administer oral thin film strip. rsci is also expecting to have its first a